Why the study?
Does a losartan-based regimen improve insulin sensitivity and peripheral vascular hypertrophy compared to an atenolol-based regimen in hypertensive patients with left ventricular hypertrophy?
Population
70 hypertensive patients with electrocardiographic left ventricular hypertrophy
Comparison
Losartan-based regimen for up to 3 years vs Atenolol-based regimen for up to 3 years
Design
RCT, blinded treatment
Follow-up
3 years
Authors
Loading...
Losartan better preserves insulin sensitivity and vascular structure than atenolol in LVH hypertension; extends ARB metabolic advantages in RCTs.
Does a losartan-based regimen improve insulin sensitivity and peripheral vascular hypertrophy compared to an atenolol-based regimen in hypertensive patients with left ventricular hypertrophy?
In hypertensive patients with left ventricular hypertrophy, losartan preserves insulin sensitivity and prevents peripheral vascular hypertrophy better than atenolol, potentially explaining the lower incidence of new-onset diabetes seen with losartan.
Olsen et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: